BETA DRUGS LIMITED

BDL/PKL/SEC/2019
13th May, 2019

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/l, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Sub: Audited Standalone and Consolidated Financial Results for the half year and year ended on 31st March, 2019 under Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015

Dear Sir/Madam
Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the company at their meeting held on Monday, 13th May, 2019 had considered and approved the Audited Standalone and Consolidated Financial Results for the half year and year ended on 31st March, 2019.

Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following:

1. Independent Auditor Report of Standalone Financial Results for the half year ended and year ended on 31st March, 2019.
2. Independent Auditor Report of Consolidated Financial Results for the half year ended and year ended on 31st March, 2019.
3. Audited Standalone and Consolidated Financial Results for the half year and year ended on 31st March, 2019.
4. Declaration for un-modified opinion on Audited Standalone and Consolidated Financial Results for the half year and year ended on 31st March, 2019

The meeting of the Board of Directors commenced at 12.30 p.m. and concluded at 5:30 p.m.

This is for your information and appropriate dissemination.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Beta Drugs Limited
Company Secretary
ACS - 24684

Rajni Brar
Company Secretary

CIN No.: U24230HP2005PLC028969
Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483
Export & Mktd Office : 1101, 11th Floor, Peninsula Park, Andheri West, Mumbai - 400053, Phone No. : +91-022-62360443
Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196
Website :- www.betadrugslimited.com www.adleylab.com
E-Mail :- info@betadrugslimited.com sales@adleylab.com

KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS
"A Peer Review Firm"
GSTIN : 04AAFFK0327HIZT

Ref. No. .... Dated ....

Auditor's Report On half yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board Of Directors Of
Beta Drugs Limited
Village Nandpur
Lodhimajra Road
Baddi, Distt Solan
H.P.-174101

We have audited the half yearly financial results of **M/s Beta Drugs Limited** for the half year ended **31st March, 2019** and for the period from **1st April, 2018 to 31st March, 2019**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These half yearly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34)for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.
We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
In our opinion and to the best of our information and according to the explanations given to us these half yearly financial results as well as the year to date results:
i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
ii. give a true and fair view of the net profit and other financial information for the half year ended **31st March, 2019** as well as the year to date results for the period from **1st April, 2018 to 31st March, 2019**.

For Kalra Rai & Associates.
Chartered Accountants
(FR No. 008859N)
Chartered Accountants
M. No. 87438

Lajpat Rai Kalra
(Partner)
Membership Number: 087438
Chandigarh
Date: 13/05/2019

KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS
"A Peer Review Firm"
GSTIN : 04AAFFK0327HIZT

Ref. No. .... Dated ....

Auditor's Report On consolidated audited half yearly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Beta Drugs Limited
Village Nandpur
Lodhimajra Road
Baddi, Distt Solan
H.P.-174101

1. We have audited the accompanying Statement of Consolidated Financial Results of **Beta Drugs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the half year ended **31st March, 2019** and for the period from **1st April, 2018 to 31st March, 2019** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related interim consolidated financial statements which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"),prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim consolidated financial statements.

3. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act 2013. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

4. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Parent's internal financial control with reference to the Statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

KALRA RAI & ASSOCIATES Chartered Accountants M. No. 87438

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 6 below, is sufficient and appropriate to provide a basis for our audit opinion.

5. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements of subsidiaries referred to in paragraph below, the Statement:

a. includes the results of the following entities:

(i) Adley Formulations Pvt Ltd (a wholly owned subsidiary)

b. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

c. gives a true and fair view in conformity with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and other financial information of the Group for the half year ended 31st March, 2019 and for the period from **1st April, 2018 to 31st March, 2019.**

6. We have audited the interim financial statements of 1 subsidiary (5 months beginning from 01st November 2018) included in the consolidated financial results whose interim financial statements reflect total assets of Rs. 19,64,02,379.96 as at 31st March, 2019, total revenues of Rs 7,93,88,871.53, total net profit / (loss) after tax of Rs 32,57,875.89, total comprehensive income/ loss of Rs. Nil (as the Company is newly incorporated) respectively for the half year ended 31st March, 2019 and for the period from 1st November, 2018 to 31st March, 2019 cash flows (net) of Rs. 38,36,052.30 are considered in the consolidated financial results, whose interim financial statements have been audited by us. The interim financial statements / financial information/financial results of these branches and joint operations have been audited by the branch auditors and other auditors whose reports have been furnished to us or other auditors, and our opinion in so far as it relates to the amounts and disclosures included in respect of these branches and joint operations, is based solely on the report of such branch auditors and other auditors and the procedures performed by us as stated in paragraph 3 above.

Our opinion on the Statement is not modified in respect of the above matters.

7. The Statement includes the result for the half year ended 31st March, 2019 being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures upto the first half year of the current financial year which was subject to limited review by us.

For Kalra Rai & Associates.
Chartered Accountants
(FR No. 008859N)

KALRA RAI & ASSOCIATES
Chartered Accountants
M. No. 87438

Lajpat Rai Kalra
(Partner)
Membership Number: 087438
Chandigarh
Date: 13/05/2019

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 174101
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
Cin : L24230HP2005PLC028969

Audited Financial Results for the period ended 31st March 2019

(Amount in Rs.)

Sr. No	Particulars	Half Year Ended (Standalone)		Year Ended (Standalone)		Year Ended (Consolidated)
		31/03/2019 (Audited)	31/03/2018 (Audited)	31/03/2019 (Audited)	31/03/2018 (Audited)	31/03/2019 (Audited)
I.	Revenue From Operations	28,70,07,341.22	29,16,27,818.64	58,04,86,838.99	50,56,67,871.26	65,92,90,672.52
II.	Other Income	1,66,439.77	22,26,262.53	31,57,848.77	24,43,898.26	37,42,886.77
III.	**Total Revenue (I+II)**	**28,71,73,780.99**	**29,38,54,081.17**	**58,36,44,687.76**	**50,81,11,769.52**	**66,30,33,559.29**
IV.	**Expenses**					
a)	Cost of Materials Consumed	15,91,57,217.09	16,20,07,801.77	33,11,92,739.65	27,86,22,734.42	37,09,54,107.26
b)	Purchase of Stock-in-Trade	-	-		-	
c)	(Increase)/Decrease in Stock of Finished Goods/WIP	(2,12,34,162.86)	(69,20,194.00)	(2,67,31,181.11)	(67,76,658.00)	(3,66,80,420.21)
d)	Other Manufacturing Expenses	4,16,11,816.26	3,58,30,491.55	7,36,95,199.13	6,38,10,807.26	7,94,64,541.99
e)	Employee benefit expenses	1,82,27,572.72	1,26,87,414.63	3,41,73,569.73	1,88,27,475.77	5,26,88,637.73
f)	Finance Cost	28,89,284.19	60,13,389.07	73,36,363.47	1,01,42,990.07	1,43,11,641.37
g)	Depreciation & amortisation expenses	1,23,14,965.89	1,16,57,454.95	2,42,32,093.54	1,85,06,706.56	2,84,15,646.53
h)	Other expenses	4,17,13,240.64	87,01,802.91	6,50,84,359.56	5,66,20,793.39	7,48,15,325.84
	Total Expenses	**25,46,79,933.93**	**22,99,78,160.88**	**50,89,83,143.97**	**43,97,54,849.47**	**58,39,69,480.50**
V.	**Profit before exceptional and extraordinary items and tax (III-IV)**	**3,24,93,847.06**	**6,38,75,920.29**	**7,46,61,543.79**	**6,83,56,920.05**	**7,90,64,078.79**
VI.	Exceptional Items	-	-	-	-	-
VII.	**Profit before extraordinary items and tax (V-VI)**	**3,24,93,847.06**	**6,38,75,920.29**	**7,46,61,543.79**	**6,83,56,920.05**	**7,90,64,078.79**
VIII.	Extraordinary Items	-	-	-	-	-
IX.	**Profit before tax (VII-VIII)**	**3,24,93,847.06**	**6,38,75,920.29**	**7,46,61,543.79**	**6,83,56,920.05**	**7,90,64,078.79**
X.	**Tax Expenses**					
a)	Current year tax	65,02,246.96	69,68,594.95	1,53,70,422.70	1,39,37,189.89	1,69,04,470.60
b)	MAT credit/Deferred tax	(1,69,16,753.76)	(66,08,467.35)	(1,78,49,803.76)	(1,32,16,934.69)	(1,82,39,192.57)
XI.	**Profit (Loss) for the period from continuing operations (IX-X)**	**4,29,08,353.86**	**6,35,15,792.69**	**7,71,40,924.85**	**6,76,36,664.85**	**8,03,98,800.76**
XII.	**Profit (Loss) from discontinuing operations**	-	-	-	-	-
XIII.	Tax expense of discontinuing operations	-	-	-	-	-
XIV.	**Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)**	-	-	-	-	
XV.	**Net Profit/(Loss) for the period (XI+XIV)**	**4,29,08,353.86**	**6,35,15,792.69**	**7,71,40,924.85**	**6,76,36,664.85**	**8,03,98,800.76**
XVI.	**Earning per share**					
a)	Basic	4.96	7.34	8.92	7.82	9.30
b)	Diluted	4.96	7.34	8.92	7.82	9.30
XVIII.	**Paid up equity share captial**	8,64,95,000.00	8,64,95,000.00	8,64,95,000.00	8,64,95,000.00	8,64,95,000.00
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	31,94,65,064.64	24,23,24,139.79	31,94,65,064.64	24,23,24,139.79	32,27,22,940.54

NOTES:

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 13th May 2019 and the same have been audited by the peer reviewed Auditors of the company.

2 The company is engaged in a single business segment i.e. Pharmaceuticals.

3 Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN : [illegible])
Chartered Accountants
M. No. 87438
LAJPAT RAI KALRA
PARTNER
Membership No. : 087438
Place : Chandigarh
Date : 13.05.2019

V.K. Batra

VIJAY KUMAR BATRA
MANAGING DIRECTOR
DIN : 01083215

For and on Behalf of Board of Directors

BALWANT SINGH
DIRECTOR
DIN : 01089968

BETA DRUGS LIMITED
Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 174101
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
Cin : L24230HP2005PLC028969

Audited Statement of Assets & Liabilities

(Amount in Rs.)

Particulars	Year Ended (Standalone) 31-Mar-19 Audited	Year Ended (Standalone) 31-Mar-18 Audited	Year Ended (Consolidated) 31-Mar-19 Audited
1. EQUITY AND LIABILITIES			
(A) Shareholder's Funds			
(a) Share Capital	8,64,95,000.00	8,64,95,000.00	8,64,95,000.00
(b) Reserves and Surplus	31,94,65,064.64	24,23,24,139.79	32,27,22,940.54
(c)Money recevied against share warrants			
Sub-total-Shareholders' funds	**40,59,60,064.64**	**32,88,19,139.79**	**40,92,17,940.54**
(B) Non- Current Liabilities			
(a) Long-term borrowings	5,27,13,933.16	2,75,15,726.91	7,36,31,274.21
(b) Deferred tax liabilities (Net)	-	14,99,675.95	-
(c) Other Long term liabilities	25,00,000.00	25,00,000.00	1,84,68,275.00
(d) Other Long term Provisions			
Sub-total-Non- current liabilities	**5,52,13,933.16**	**3,15,15,402.86**	**9,20,99,549.21**
(C) Current Liabilities			
(a) Short-term borrowings	1,15,66,270.95	3,58,65,012.02	10,87,58,919.65
(b) Trade Payable	10,16,16,650.51	6,10,58,593.71	13,11,70,898.71
(c) Other current liabilities	6,63,49,604.44	3,52,89,931.92	7,67,79,945.85
(d) Short-term provisions	58,33,606.00	32,54,956.00	73,55,573.90
Sub-total-current liabilites	**18,53,66,131.90**	**13,54,68,493.65**	**32,40,65,338.11**
TOTAL - EQUITY AND LIABILITIES	**64,65,40,129.70**	**49,58,03,036.30**	**82,53,82,827.86**
2. ASSETS			
(A) Non-current assets			
(a) Fixed assets			
(i) Property, Plant & Equipment	11,76,88,316.93	13,18,70,936.38	17,31,93,033.18
(ii) Intangible assets		-	
(iii) Capital work-in-progress	15,04,15,738.88	1,34,74,652.00	15,04,15,738.88
(b) Long Term Loan & Advance	4,25,87,046.70	2,72,16,624.00	4,25,87,046.70
(c) Other Non Current Assets	1,61,20,592.62		35,20,592.62
(d) Deferred tax Assets	9,79,705.11		13,69,093.92
Sub-total-Non-current assets	**32,77,91,400.24**	**17,25,62,212.38**	**37,10,85,505.30**
(B) Current Assets			
(a) Inventories	6,40,97,049.94	2,80,34,802.00	9,52,93,672.65
(b) trade receivable	17,32,94,672.62	14,44,22,475.31	25,02,84,489.20
(c) cash and bank balance	2,91,80,194.79	11,90,66,796.46	3,30,16,247.09
(d) Short-term loan and advances	1,36,06,337.48	1,41,29,962.48	1,53,78,352.48
(e) Other current assets	3,85,70,474.63	1,75,86,787.67	6,03,24,561.15
Sub-total-current assets	**31,87,48,729.46**	**32,32,40,823.92**	**45,42,97,322.57**
TOTAL - ASSETS	**64,65,40,129.70**	**49,58,03,036.30**	**82,53,82,827.86**

1. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 13th May 2019 and the same have been audited by the peer reviewed Auditors of the company.
2. Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN : 008559N)

KALRA RAI & ASSOCIATES Chartered Accountants M. No. 87438

LAJPAT RAI KALRA
PARTNER
Membership No. : 087438
Place : Chandigarh
Date : 13.05.2019

V.K. Batra

VIJAY KUMAR BATRA
MANAGING DIRECTOR
DIN : 01083215

For and on Behalf of Board of Directors

BALWANT SINGH
DIRECTOR
DIN : 01089968

BETA DRUGS LIMITED

BDL/PKL/SEC/2019
13th May, 2019

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/l, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Sub: Declaration Pursuant to Regulation 33 (3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015

Dear Sir/Madam

In accordance with Regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we hereby declare that M/s Kalra Rai & Associates, Chartered Accountant (Firm Registration Number 008859N), Statutory Auditors of the Company have issued an Auditors Report with unmodified opinion on Standalone and Consolidated Audited Financial Results of the Company for the half year and year ended 31.03.2019 approved at the Board Meeting held on 13th May, 2019.

Kindly take the same on record.

Thanking You

Your's faithfully
For Beta Drugs Ltd.

Vijay Kumar Batra
Managing Director
DIN NO. 01083215

BETA DRUGS LIMITED

FORM A (for audit report with unmodified opinion)

1.	Name of the Company	BETA DRUGS LIMITED
2.	Annual financial statement for the year ended	31st March, 2019
3.	Type of Audit observation	Un modified
4.	Frequency of observation	N/A
5.	To be signed by- Managing Director	Vijay Kumar Batra
	CFO	Jayant Kumar
	Auditor of the Company	KALRA RAI & ASSOCIATES Chartered Accountants M.No. 87438 Lajpat Rai Kalra Partner Membership No. 087438 (Firm Registration Number 008859N)
	Audit Committee Chairman	Rohit Parti